Heart Disease Trial, Recruiting NCT04124120 Sponsor: Weill Medical College of Cornell University Condition: Heart Disease
Back to Heart Disease

Heart Disease Trial, Recruiting

NCT04124120
Recruiting Not Applicable 🇦🇺 Australian site

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Women aged 18 or older
  • People having coronary artery bypass grafting (a type of heart surgery to improve blood flow) as the only procedure being performed
  • People having this type of heart surgery for the first time
  • People with significant blockage or disease in specific major heart arteries (the left main coronary artery, or the left anterior descending and circumflex arteries, with or without disease in the right coronary artery)

Who may not be able to join:

  • Men
  • People who would only need a single bypass graft
  • People requiring emergency surgery
  • People who had a heart attack within 72 hours before the planned surgery
  • People whose heart pumping function is significantly reduced (below 35%) (confirm with trial site)
  • People needing any additional heart or non-heart procedures at the same time
  • People who have had previous heart surgery
  • People with serious kidney failure requiring dialysis, liver failure, respiratory failure, cancer, or any other condition that is likely to reduce life expectancy to less than 5 years
  • People for whom the saphenous vein (a leg vein) cannot be used, or for whom both the radial artery (wrist) and right internal thoracic artery (chest) cannot be used as grafts
  • People expected to need a specific artery-clearing technique called coronary thrombo-endarterectomy during surgery
  • People whose treatment plan includes a combined surgical and non-surgical approach to restoring heart blood flow (known as hybrid revascularisation)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 8 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Mario Gaudino, Prof/PhD/MD, Weill Medical College of Cornell University

Phone: 212.746.1812

Australian sites

Victorian Heart Hospital, Clayton,
The University of Melbourne, Melbourne,

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
17 April 2023
Est. completion
1 March 2030

Where this trial is recruiting

🇦🇺 Australia 🇦🇹 Austria 🇧🇷 Brazil 🇨🇦 Canada 🇨🇳 China 🇭🇷 Croatia 🇨🇿 Czechia 🇩🇰 Denmark 🇩🇪 Germany 🇮🇳 India 🇮🇱 Israel 🇮🇹 Italy 🇯🇵 Japan 🇳🇱 Netherlands North Macedonia 🇵🇱 Poland 🇵🇹 Portugal 🇷🇺 Russia 🇷🇸 Serbia 🇸🇬 Singapore 🇰🇷 South Korea 🇪🇸 Spain 🇸🇪 Sweden 🇹🇼 Taiwan 🇬🇧 United Kingdom 🇺🇸 United States

2 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Primary outcome for aim 1: Death from any cause, any stroke, non-procedural myocardial infarction, repeat revascularization and hospital readmission for acute coronary syndrome or heart failure.; Primary outcome for aim 2: Disease-specific quality of life

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov